- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT02693145
Cooperative Re-Engagement Controlled Trial (CoRECT) (CoRECT)
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
Methods summary: Health departments will generate an out-of-care list using HIV laboratory surveillance data; collaborating clinics will concurrently generate out-of-care lists using appointment data. The combined out-of-care list will be reconciled by the health department and clinics, and discussed at monthly case conferences. All individuals determined to be out-of care will be randomized to receive either: (1) usual linkage and engagement in care services (standard of care [SOC]); or (2) an active health department field services intervention in addition to SOC. The active intervention activities will vary among jurisdictions; however all sites will include field services to locate, contact, and provide assistance, including a same-day appointment, to access HIV medical care.
Study design: Each site will enroll 600 out-of-care HIV-infected individuals (300 per arm) during a two-year enrollment period. An out-of-care individual will be defined as: (1) a person who has received HIV medical care at a CoRECT clinic and then disengages from care; or (2) a person with newly diagnosed HIV infection who has an appointment at a CoRECT clinic, but has not linked to medical care within 90 days.
Intervention: Individuals randomized to the intervention arm will receive field services to locate, contact, and provide assistance to access HIV medical care. Services provided as part of the intervention will vary by jurisdiction, but may include assistance with expedited medical appointments, transportation, access to community resources such as traditional case management, strengths-based case management, or financial incentives (Appendix A).
Primary outcomes: The following outcomes will be compared between out-of-care HIV-infected individuals receiving the study intervention to those receiving usual services:
- Attend 1 clinic visit within 90 days;
- Remain engaged in care, defined as 2 clinic visits at least 3 months apart within 12 months;
- Achieve viral load suppression within 12 months;
- Achieve durable viral load suppression, defined as 2 consecutive suppressed viral load results at least 3 months apart within 18 months
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
Connecticut
-
Hartford, Connecticut, Spojené státy, 06106
- Connecticut Department of Public Health
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02108
- Massachusetts Department of Public Health
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19104
- Philadelphia Department of Health
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
Residents within the health department jurisdiction who have received HIV medical care at a CoRECT clinic and then disengage by either of the following definitions:
- Clinic definition: did not have a visit with a prescribing provider for 6 months.
- Health department definition: no CD4 or viral load test result reported to health department surveillance for more than 6 months.
Residents within the health department jurisdiction with newly diagnosed HIV infection who have not linked to medical care within 90 days and have either:
- Received, but did not attend, an appointment at a CoRECT clinic; or
- Attended an enrollment visit but did not receive medical care at a CoRECT clinic.
Exclusion Criteria:
- Deceased
- Out of jurisdiction
- Changed providers
- Incarcerated
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Výzkum zdravotnických služeb
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Dvojnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Žádný zásah: standard of care (SOC) arm
Individuals found to be out of HIV medical care will receive standard of care to re-engage.
This will not include use of disease intervention specialist to locate and recruit back to HIV medical care or use of the Anti-Retroviral Treatment and Access to Services (ARTAS) intervention.
|
|
|
Experimentální: Intervention arm
Individuals randomized to the intervention arm will receive field services to locate, contact, and provide assistance to access HIV medical care.
Intervention may include use of disease intervention specialist to locate and recruit back to HIV medical care or use of the Anti-Retroviral Treatment and Access to Services (ARTAS) intervention.
|
Anti-Retroviral Treatment and Access to Services (ARTAS) is an individual-level, multi-session, time-limited intervention with the goal of linking recently diagnosed persons with HIV to medical care soon after receiving their positive test result.
ARTAS is based on the Strengths-based Case Management (SBCM) model, which is rooted in Social Cognitive Theory (particularly self-efficacy) and Humanistic Psychology.
SBCM is a model that encourages the client to identify and use personal strengths; create goals for himself/herself; and establish an effective, working relationship with the Linkage Coordinator (LC).
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Attend one clinic visit
Časové okno: within 90 days of randomization
|
Patient will attend one clinical visit at CoRECT clinic to receive HIV medical care
|
within 90 days of randomization
|
|
Remain engaged in care
Časové okno: defined as 2 clinic visits at least 3 months apart within 12 months
|
Two or more medical visits at least 3 months apart within 12 months to demonstrate patient remains engaged in HIV medical care
|
defined as 2 clinic visits at least 3 months apart within 12 months
|
|
Viral load suppression
Časové okno: within 12 months
|
Does the patient achieve viral load suppression within 12 months of randomization
|
within 12 months
|
|
Achieve durable viral load suppression
Časové okno: defined as 2 consecutive suppressed viral load results at least 3 months apart within 18 months
|
Achieve durable viral load suppression, defined as 2 consecutive suppressed viral load results at least 3 months apart within 18 months
|
defined as 2 consecutive suppressed viral load results at least 3 months apart within 18 months
|
Spolupracovníci a vyšetřovatelé
Publikace a užitečné odkazy
Obecné publikace
- Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11;365(6):493-505. doi: 10.1056/NEJMoa1105243. Epub 2011 Jul 18.
- Gardner LI, Metsch LR, Anderson-Mahoney P, Loughlin AM, del Rio C, Strathdee S, Sansom SL, Siegal HA, Greenberg AE, Holmberg SD; Antiretroviral Treatment and Access Study Study Group. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS. 2005 Mar 4;19(4):423-31. doi: 10.1097/01.aids.0000161772.51900.eb.
- The White House Office of National AIDS Policy. National HIV/AIDS Strategy. Available at: http://www.whitehouse.gov/administration/eop/onap/nhas. Accessed: 30 January 2015.
- Bradley H, Hall HI, Wolitski RJ, Van Handel MM, Stone AE, LaFlam M, Skarbinski J, Higa DH, Prejean J, Frazier EL, Patel R, Huang P, An Q, Song R, Tang T, Valleroy LA. Vital Signs: HIV diagnosis, care, and treatment among persons living with HIV--United States, 2011. MMWR Morb Mortal Wkly Rep. 2014 Nov 28;63(47):1113-7.
- Skarbinski J, Rosenberg E, Paz-Bailey G, Hall HI, Rose CE, Viall AH, Fagan JL, Lansky A, Mermin JH. Human immunodeficiency virus transmission at each step of the care continuum in the United States. JAMA Intern Med. 2015 Apr;175(4):588-96. doi: 10.1001/jamainternmed.2014.8180.
- Gardner LI, Marks G, Craw JA, Wilson TE, Drainoni ML, Moore RD, Mugavero MJ, Rodriguez AE, Bradley-Springer LA, Holman S, Keruly JC, Sullivan M, Skolnik PR, Malitz F, Metsch LR, Raper JL, Giordano TP; Retention in Care Study Group. A low-effort, clinic-wide intervention improves attendance for HIV primary care. Clin Infect Dis. 2012 Oct;55(8):1124-34. doi: 10.1093/cid/cis623. Epub 2012 Jul 24.
- Gardner LI, Giordano TP, Marks G, Wilson TE, Craw JA, Drainoni ML, Keruly JC, Rodriguez AE, Malitz F, Moore RD, Bradley-Springer LA, Holman S, Rose CE, Girde S, Sullivan M, Metsch LR, Saag M, Mugavero MJ; Retention in Care Study Group. Enhanced personal contact with HIV patients improves retention in primary care: a randomized trial in 6 US HIV clinics. Clin Infect Dis. 2014 Sep 1;59(5):725-34. doi: 10.1093/cid/ciu357. Epub 2014 May 15.
- Dombrowski JC. Testing, Linkage and Retention in Care: Getting Control of the Cascade in Seattle. National Summit on HIV and Viral Hepatitis Diagnosis, Prevention, and Access to Care, Washington, DC, November 26-8, 2012.
- Udeagu CC, Webster TR, Bocour A, Michel P, Shepard CW. Lost or just not following up: public health effort to re-engage HIV-infected persons lost to follow-up into HIV medical care. AIDS. 2013 Sep 10;27(14):2271-9. doi: 10.1097/QAD.0b013e328362fdde.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- RNA virové infekce
- Virová onemocnění
- Infekce
- Infekce přenášené krví
- Přenosné nemoci
- Pohlavně přenosné choroby, virové
- Pohlavně přenosné nemoci
- Lentivirové infekce
- Retroviridae infekce
- Syndromy imunologické nedostatečnosti
- Onemocnění imunitního systému
- Pomalá virová onemocnění
- HIV infekce
- Syndrom získané immunití nedostatečnisti
- Antiinfekční látky
- Antivirová činidla
- Antiretrovirová činidla
Další identifikační čísla studie
- FOA PS14-001
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Virus lidské imunodeficience
-
Jinling Hospital, ChinaNeznámýCrohnova nemoc | Methylace | Illumina Human Methylation 850k BeadChipČína
-
Merck Sharp & Dohme LLCDokončenoUroteliální karcinom Associated 1 RNA, Human
-
KTO Karatay UniversityNáborHPV (Human Papillomavirus) - asociovanýTurecko (Türkiye)
-
Ufuk UniversityNáborStav imunizace proti HPV | HPV (Human Papillomavirus) - asociovanýTurecko (Türkiye)
-
Paul W. Read, MDUkončenoOrofaryngeální spinocelulární karcinom (OPSCCA) | HPV (Human Papillomavirus) - asociovanýSpojené státy
-
Second Affiliated Hospital, School of Medicine,...First People's Hospital of Hangzhou; Women's Hospital School Of Medicine Zhejiang... a další spolupracovníciZatím nenabírámeFotodynamická terapie (PDT) | HPV (Human Papillomavirus) - asociovaný | CIN 2 | Hsil, vysoce kvalitní spinocelus intraepiteliální lézeČína
-
M.D. Anderson Cancer CenterZatím nenabírámeHPV (Human Papillomavirus) - asociovanýSpojené státy
-
Vastra Gotaland RegionNáborMyelodysplastický syndrom | Akutní myeloidní leukémie | Difuzní velký B buněčný lymfom (DLBCL) | HPV (Human Papillomavirus) - asociovaný | Příjemci transplantace alogenních kmenových buněkŠvédsko
-
QurasenseNáborScreening rakoviny děložního čípku | HPV infekce | HPV | HPV infekce | Screeningový test | HPV DNA | Infekce HPV 16 | HPV (Human Papillomavirus) - asociovaný | Rakovina děložního čípku Cin Grade | Vysoce rizikové HPV | Rakovina děložního čípku (Včasná detekce)Spojené státy
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbDokončenoStádium IVA spinocelulárního karcinomu ústní dutiny | Stádium IV hypofaryngeálního spinocelulárního karcinomu | Stádium IVA laryngeálního spinocelulárního karcinomu | Fáze IVA orofaryngeálního spinocelulárního karcinomu | Stádium IVB Laryngeální spinocelulární karcinom | Stádium IVB orofaryngeální... a další podmínkySpojené státy
Klinické studie na Anti-Retroviral Treatment and Access to Services (ARTAS)
-
University of Alabama at BirminghamJohns Hopkins University; Birmingham AIDS Outreach; AIDS UnitedDokončenoHIV infekce | Ztráta péče o HIV k následnému sledování